Overview
Galapagos NV, based in Belgium, is a prominent biotechnology company focused on the discovery and development of small molecule medicines with novel modes of action. The company's primary industry lies in pharmaceutical research and development, particularly in areas such as inflammation, fibrosis, and other therapeutic fields. A key project of Galapagos includes its work on filgotinib, a selective JAK1 inhibitor, developed for the treatment of rheumatoid arthritis and other inflammatory diseases. Galapagos NV is notable for its innovative approach in leveraging proprietary, target discovery platform and collaborating with industry leaders, which significantly accelerates its drug development processes. This strategic focus not only enhances Galapagos NV’s pipeline but also strengthens its position in the global biotech landscape.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Galapagos NV as of 30 June 2025 is 275.61 MM.
- The operating income for Galapagos NV as of 30 June 2025 is -331.52 MM.
- The net income for Galapagos NV as of 30 June 2025 is -284.27 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 275.61 | -331.52 | -284.27 |
2025-03-31 | 288.19 | -312.67 | -169.54 |
2024-12-31 | 275.65 | -187.09 | 74.08 |
2024-09-30 | 260.09 | -164.32 | 206.33 |
2024-06-30 | 261.40 | -121.08 | 282.59 |
2024-03-31 | 243.58 | -99.55 | 278.71 |
2023-12-31 | 239.72 | -77.47 | 211.70 |
2023-09-30 | 543.97 | -151.42 | -153.07 |
2023-06-30 | 85.92 | -52.32 | -157.34 |
2023-03-31 | 163.48 | -88.44 | -181.47 |
2022-12-31 | 241.25 | -131.06 | -217.99 |
2022-09-30 | 577.15 | -98.19 | 5.57 |
2022-06-30 | 505.14 | -129.51 | -80.60 |
2022-03-31 | 507.30 | -126.63 | -125.90 |
2021-12-31 | 234.38 | -171.57 | -103.23 |
2021-09-30 | 473.99 | -177.39 | -177.47 |
2021-06-30 | 537.31 | -141.79 | -194.76 |
2021-03-31 | 488.38 | -183.21 | -245.47 |
2020-12-31 | 478.05 | -178.63 | -305.44 |
2020-09-30 | 455.26 | -191.96 | -363.03 |
2020-06-30 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | -2.57 | -2.57 |
2024-12-31 | 1.12 | 1.12 |
2024-09-30 | 3.14 | 3.13 |
2024-06-30 | 4.29 | 4.29 |
2024-03-31 | 4.24 | 4.23 |
2023-12-31 | 3.21 | 3.21 |
2023-09-30 | -2.37 | -2.37 |
2023-06-30 | -2.39 | -2.39 |
2023-03-31 | -2.76 | -2.77 |
2022-12-31 | -3.32 | -3.32 |
2022-09-30 | 0.08 | 0.09 |
2022-06-30 | -1.23 | -1.22 |
2022-03-31 | -1.91 | -1.91 |
2021-12-31 | -1.58 | -1.58 |
2021-09-30 | -2.71 | -2.71 |
2021-06-30 | -2.98 | -2.98 |
2021-03-31 | -3.76 | -3.76 |
2020-12-31 | -4.69 | -4.69 |
2020-09-30 | -5.62 | -5.62 |
2020-06-30 | 1.28 | 1.22 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Galapagos NV as of 30 June 2025 is -278.55 MM.
- The cash from investing activities for Galapagos NV as of 30 June 2025 is 284.37 MM.
- The cash from financing activities for Galapagos NV as of 30 June 2025 is -4.30 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -278.55 | 284.37 | -4.30 |
2025-03-31 | -236.20 | 275.68 | -4.77 |
2024-12-31 | -320.03 | 220.60 | -4.92 |
2024-09-30 | -327.52 | 228.65 | -4.51 |
2024-06-30 | -374.55 | 354.62 | -5.49 |
2024-03-31 | -433.54 | 389.52 | -5.98 |
2023-12-31 | -405.97 | 71.19 | -5.00 |
2023-09-30 | -518.97 | 12.89 | -5.73 |
2023-06-30 | -517.09 | -352.22 | -2.87 |
2023-03-31 | -533.44 | -600.73 | -1.65 |
2022-12-31 | -500.54 | -1,245.51 | -1.49 |
2022-09-30 | -484.45 | -1,715.58 | -1.01 |
2022-06-30 | -504.44 | -1,221.87 | -2.76 |
2022-03-31 | -444.59 | -892.07 | -4.38 |
2021-12-31 | -503.83 | 541.24 | -3.88 |
2021-09-30 | -377.22 | 1,118.76 | -1.00 |
2021-06-30 | -420.64 | 726.54 | 0.32 |
2021-03-31 | -479.67 | 327.51 | 18.59 |
2020-12-31 | -427.34 | 757.29 | 22.04 |
2020-09-30 | -510.31 | -3,110.06 | 385.62 |
2020-06-30 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- The p/e for Galapagos NV as of 30 June 2025 is -9.25.
- The p/book for Galapagos NV as of 30 June 2025 is 0.57.
- The p/tbv for Galapagos NV as of 30 June 2025 is 0.62.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -9.25 | 0.57 | 0.62 |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | -10.76 | 0.63 | 0.68 |
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
- The ebit/ev for Galapagos NV as of 30 June 2025 is -0.12.
- The ebit (3y)/ev for Galapagos NV as of 30 June 2025 is -0.07.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.12 | -0.07 |
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | 0.00 | -0.04 |
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 |
Management Effectiveness
- The roa for Galapagos NV as of 30 June 2025 is -0.04.
- The roe for Galapagos NV as of 30 June 2025 is -0.10.
- The roic for Galapagos NV as of 30 June 2025 is -0.06.
- The croic for Galapagos NV as of 30 June 2025 is 0.01.
- The ocroic for Galapagos NV as of 30 June 2025 is -0.09.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.04 | -0.10 | -0.06 | 0.01 | -0.09 |
2025-03-31 | 0.02 | -0.06 | 0.03 | -0.04 | -0.11 |
2024-12-31 | 0.05 | 0.03 | 0.07 | -0.04 | -0.11 |
2024-09-30 | 0.06 | 0.08 | 0.10 | -0.01 | -0.13 |
2024-06-30 | 0.06 | 0.11 | 0.10 | -0.02 | -0.15 |
2024-03-31 | 0.04 | 0.08 | 0.08 | -0.12 | -0.14 |
2023-12-31 | -0.03 | -0.06 | -0.06 | -0.20 | -0.20 |
2023-09-30 | -0.03 | -0.06 | -0.06 | -0.34 | -0.20 |
2023-06-30 | -0.04 | -0.06 | -0.06 | -0.34 | -0.20 |
2023-03-31 | -0.04 | -0.07 | -0.07 | -0.44 | -0.21 |
2022-12-31 | 0.00 | 0.00 | 0.00 | -0.81 | -0.18 |
2022-09-30 | -0.02 | 0.00 | 0.00 | -0.81 | -0.18 |
2022-06-30 | -0.02 | -0.03 | -0.03 | -0.63 | -0.19 |
2022-03-31 | -0.02 | -0.05 | -0.05 | -0.49 | -0.17 |
2021-12-31 | -0.03 | -0.04 | -0.04 | 0.03 | -0.14 |
2021-09-30 | -0.03 | -0.07 | -0.07 | 0.28 | -0.16 |
2021-06-30 | -0.03 | -0.07 | -0.07 | 0.10 | -0.16 |
2021-03-31 | -0.04 | -0.09 | -0.09 | -0.07 | -0.18 |
2020-12-31 | -0.05 | -0.11 | -0.11 | 0.10 | -0.16 |
2020-09-30 | -0.06 | -0.32 | -0.13 | -1.28 | -0.19 |
2020-06-30 | 0.06 | 0.07 | 0.03 | 0.44 | 1.12 |
Gross Margins
- The gross margin for Galapagos NV as of 30 June 2025 is 0.45.
- The net margin for Galapagos NV as of 30 June 2025 is -0.59.
- The operating margin for Galapagos NV as of 30 June 2025 is -1.08.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.45 | -0.59 | -1.08 |
2025-03-31 | -0.34 | 0.27 | -0.68 |
2024-12-31 | -0.27 | 0.79 | -0.63 |
2024-09-30 | -0.14 | 1.08 | -0.48 |
2024-06-30 | -0.08 | 1.14 | -0.41 |
2024-03-31 | -0.01 | 0.88 | -0.37 |
2023-12-31 | -0.56 | -0.55 | -0.02 |
2023-09-30 | 0.10 | -0.28 | -0.28 |
2023-06-30 | 0.08 | -0.28 | -0.28 |
2023-03-31 | 0.01 | -0.33 | -0.36 |
2022-12-31 | 0.20 | 0.01 | -0.15 |
2022-09-30 | 0.10 | 0.01 | -0.15 |
2022-06-30 | 0.08 | -0.16 | -0.26 |
2022-03-31 | -0.02 | -0.25 | -0.25 |
2021-12-31 | 0.03 | -0.21 | -0.34 |
2021-09-30 | 0.10 | -0.34 | -0.35 |
2021-06-30 | 0.10 | -0.33 | -0.24 |
2021-03-31 | 0.02 | -0.49 | -0.37 |
2020-12-31 | 0.01 | -0.64 | -0.37 |
2020-09-30 | -0.05 | -0.73 | -0.39 |
2020-06-30 | 0.49 | 0.08 | 0.33 |
Identifiers and Descriptors
Central Index Key (CIK) | 1421876 |
Industry Groups
SIC 2834 - Pharmaceutical Preparations |